XENE
Xenon Pharmaceuticals Inc

2,651
Mkt Cap
$3.46B
Volume
656,547.00
52W High
$46.60
52W Low
$26.74
PE Ratio
-11.53
XENE Fundamentals
Price
$44.58
Prev Close
$44.79
Open
$45.00
50D MA
$42.51
Beta
0.79
Avg. Volume
1.06M
EPS (Annual)
-$3.01
P/B
6.17
Rev/Employee
$0.00
$2,435.58
Loading...
Loading...
News
all
press releases
Xenon Pharmaceuticals (NASDAQ:XENE) Upgraded at Wolfe Research
Wolfe Research upgraded shares of Xenon Pharmaceuticals to a "strong-buy" rating in a research report on Monday...
MarketBeat·23h ago
News Placeholder
More News
News Placeholder
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Buy" from Analysts
Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) has been given a consensus rating of "Buy" by the thirteen brokerages that are covering the company, MarketBeat reports. One research...
MarketBeat·6d ago
News Placeholder
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data
Key PointsConnecticut-based Braidwell sold 1,779,953 Xenon Pharmaceuticals shares in the fourth quarter; the estimated transaction value was $74.76 million based on quarterly average prices...
Nasdaq News: Markets·6d ago
News Placeholder
Xenon Pharmaceuticals (XENE) Projected to Post Earnings on Thursday
Xenon Pharmaceuticals (NASDAQ:XENE) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...
MarketBeat·7d ago
News Placeholder
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)
Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the target of unusually large options trading on Wednesday. Stock traders acquired 4,063 put options on the company. This represents an...
MarketBeat·7d ago
News Placeholder
Aberdeen Group plc Has $23.25 Million Holdings in Xenon Pharmaceuticals Inc. $XENE
Aberdeen Group plc increased its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 11.1% during the third quarter, according to the company in its most recent 13F filing...
MarketBeat·8d ago
News Placeholder
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Buy" from Analysts
Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) has received an average rating of "Buy" from the fourteen research firms that are covering the firm, Marketbeat.com reports. One analyst has...
MarketBeat·1mo ago
News Placeholder
Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE)
Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) saw some unusual options trading on Wednesday. Stock traders acquired 4,063 put options on the stock. This represents an increase of 2,362...
MarketBeat·1mo ago
News Placeholder
Campbell & CO Investment Adviser LLC Takes Position in Xenon Pharmaceuticals Inc. $XENE
Campbell & CO Investment Adviser LLC purchased a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the third quarter, according to the company in its most recent...
MarketBeat·1mo ago
News Placeholder
Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 12-Month High - Time to Buy?
Xenon Pharmaceuticals (NASDAQ:XENE) Reaches New 12-Month High - Still a Buy...
MarketBeat·2mo ago
<
1
2
...
>

Latest XENE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.